Elanco Animal Health (NYSE:ELAN) versus Inhibitor Therapeutics (OTCMKTS:INTI) Financial Contrast

Elanco Animal Health (NYSE:ELAN) and Inhibitor Therapeutics (OTCMKTS:INTI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Elanco Animal Health and Inhibitor Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.71 billion	2.34	-$232.00 million	($0.50)	-44.12
Inhibitor Therapeutics	N/A	N/A	-$3.30 million	($0.01)	-5.92

Inhibitor Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Inhibitor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Inhibitor Therapeutics	N/A	-1,693.49%	-122.07%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Elanco Animal Health and Inhibitor Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1	2	9	1	2.77
Inhibitor Therapeutics	0	0	0	0	0.00

Elanco Animal Health currently has a consensus target price of $29.09, suggesting a potential upside of 31.88%. Given Elanco Animal Health’s stronger consensus rating and higher probable upside, research analysts clearly believe Elanco Animal Health is more favorable than Inhibitor Therapeutics.

Volatility and Risk

Elanco Animal Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.77, suggesting that its share price is 177% less volatile than the S&P 500.

Insider and Institutional Ownership

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats Inhibitor Therapeutics on 9 of the 14 factors compared between the two stocks.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.